🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    phase 2 mab active

    1 trial

  2. lymphokine-activated killer cells

    LISATA THERAPEUTICS, INC.

    Brain and Central Nervous System Tumors

    phase 2 mab terminated

    1 trial

  3. masitinib, masitinib, Placebo to 100mg masitinib, Placebo to 200mg masitinib

    AB Science

    Mast cell activation syndrome

    phase 2 small molecule active

    1 trial

  4. meningococcal ACWY (vaccine)

    GlaxoSmithKline

    Infections, Meningococcal

    phase 2 mab completed

    1 trial

  5. middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Norovirus Infections

    phase 2 mab active

    1 trial

  6. oritavancin

    Targanta Netherlands B.V.

    Staphylococcal Skin Infections

    phase 2 small molecule completed

    1 trial

  7. pectin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Crohn's Disease

    phase 2 small molecule terminated

    1 trial

  8. placebo PH20 SC PFS, Vyvgart 1 000 mg solution for injection in pre-filled syringe

    argenx

    Systemic Sclerosis

    phase 2 small molecule active

    1 trial

  9. pneumococcal polysaccharide and protein conjugate vaccines

    United Therapeutics Europe Ltd

    Pneumococcal Infections

    phase 2 mab completed

    1 trial

  10. rVA576

    Akari Therapeutics Plc

    Keratoconjunctivitis, Atopic

    phase 2 small molecule terminated

    1 trial

  11. rhNGF New Lyo Formulation, OXYBUPROCAINE , SODIUM CHLORIDE , rhNGF New Lyo Formulation, The placebo consists of a lyophilized product packaged in 2R siliconized glass class I vials closed with a stopper and a flip off cap and administered after reconstitution with 2mL of diluent contained into a 2R glass class I vials closed with a stopper and a flip off cap. The diluent consists of DMSO, Sesame Extract 98%, Kollifor HS 0.15%, Sodium Chloride, Water For Injection. The product is reconstituted using an ada

    Dompe' Farmaceutici S.p.A.

    Dry Eye

    phase 2 small molecule active

    1 trial

  12. riliprubart, riliprubart

    Sanofi-aventis Healthcare Pty Ltd

    Transplant Rejection

    phase 2 small molecule active

    1 trial

  13. self-expandable 125I radioactive seeds-loaded-stent

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cholangiocellular Carcinoma

    phase 2 other completed

    1 trial

  14. sham group will undergo a procedure that will closely mimic the active injection but with no penetration of the globe.

    Laboratoire HRA Pharma

    Retinitis Pigmentosa

    phase 2 small molecule active

    1 trial

  15. sham group will undergo a procedure that will closely mimic the active injection but with no penetration of the globe.

    Laboratoire HRA Pharma

    Retinitis Pigmentosa

    phase 2 small molecule active

    1 trial

  16. sodium chloride 9 mg/ml (0.9%) solution for injection, LIBTAYO 350 mg concentrate for solution for infusion.

    The George Institute

    Merkel Cell Carcinoma

    phase 2 small molecule active

    1 trial

  17. sotatercept, PL1 - Powder for injection

    Lacuna Pharma Pty Ltd

    Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)

    phase 2 small molecule active

    1 trial

  18. standard triple region

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Helicobacter Pylori Infection

    phase 2 small molecule completed

    1 trial

  19. sterile saline solution (0.9% w/v solution of NaCl in water).

    GlaxoSmithKline

    Urinary Tract Infections

    phase 2 small molecule active

    1 trial

  20. tamuzimod, tamuzimod, tamuzimod, VTX002 placebo film-coated tablets matching VTX002, tamuzimod

    Lacuna Pharma Pty Ltd

    Moderately to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  21. tauroursodeoxycholic acid (TUDCA)

    The First People's Hospital of Lianyungang

    Metabolic Dysfunction-Associated Steatotic Liver Disease Infant Development

    phase 2 small molecule active

    1 trial

  22. teclistamab, JNJ-64407564, JNJ-64407564, teclistamab, DARZALEX 1800 mg solution for injection

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  23. telaprevir

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C Virus Infection

    phase 2 small molecule terminated

    1 trial

  24. thalidomide

    Ultragenyx UK Limited

    HIV Infections

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources